Skip to Content

Label Changes for:

Emend (aprepitant) capsules

August 2014

Changes have been made to the ADVERSE REACTIONS sections of the safety label.

Detailed View: Safety Labeling Changes Approved By FDA Center for Drug Evaluation and Research (CDER)  


August 2014


Postmarketing Experience
  • Nervous system disorders: Events of ifosfamide-induced neurotoxicity have been reported after aprepitant and ifosfamide coadministration.



Clinical Trials Experience
  • section (including Table 2) was updated to include the adverse experience data from the sponsor's completed postmarketing study.


Post-Marketing Trial
  • Entire Section Updated
  • In a postmarketing, multicenter, randomized, double-blind, parallel-group, clinical study in 848 cancer patients, the aprepitant regimen (N=430) was compared with a standard of care therapy (N=418) in patients receiving a moderately emetogenic chemotherapy regimen that included...